. 2018 Dec 4;11:8605–8621. doi: 10.2147/OTT.S171724

Table 1.

Characteristics of the studies included in the meta-analysis

Study	Year	Phase	Regimen	N	Bevacizumab schedule	Overall response		Grade 3/4		Site of metastases		Primary tumor location
Study	Year	Phase	Regimen	N	Bevacizumab schedule	Events	Total	Events	Total	Liver	Lung	Colon	Rectum
Giantonio et al²¹	2007	Phase III RCT	Be + FOLFOX4 vs FOLFOX4 alone	577	10 mg/kg every 3 weeks	65	286	215	286	210	159	NR	NR
Kabbinavar et al²²	2003	Phase II RCT	Be + FU/LV vs FU/LV alone	104	5 or 10 mg/kg every 2 weeks	22	68	51	67	73	43	NR	NR
Hurwitz et al²³	2004	Phase II RCT	Be + IFL vs IFL + placebo	813	5 mg/kg every 2 weeks	180	402	334	393	NR	NR	310	92
Kabbinavar et al²⁴	2005	Phase II RCT	Be + FU/LV vs FU/LV + placebo	209	5 mg/kg every 2 weeks	27	104	87	100	NR	NR	82	18
Saltz et al²⁵	2008	Phase III RCT	Be + FOLFOX-4/XELOX vs FOLFOX-4/XELOX + placebo	1,400	7.5 mg/kg every 3 weeks	329	699	145	694	NR	NR	459	180
Stathopoulos et al²⁶	2010	Phase III RCT	Be + IFL vs IFL alone	222	7.5 mg/kg every 3 weeks	42	114	NR	NR	53	12	NR	NR
Tebbutt et al²⁷	2010	Phase III RCT	Be + capecitabine vs capecitabine alone	289	7.5 mg/kg every 3 weeks	56	147	NR	NR	117	62	100	29
Cunningham et al²⁸	2013	Phase III RCT	Be + capecitabine vs capecitabine alone	280	7.5 mg/kg every 3 weeks	27	140	53	112	88	50	96	59

Abbreviations: Be, bevacizumab; FOLFOX, oxaliplatin, fluorouracil, and leucovorin; FU/LV, fluorouracil and leucovorin; IFL, irinotecan, fluorouracil, and leucovorin; NR, not recorded; RCT, randomized controlled trial; XELOX, capecitabine and oxaliplatin.